Investor Presentaiton
Proprietary Drug Discovery (Jubilant Therapeutics)
■ Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune
diseases. Our advanced discovery engine integrates structure-based design and computational architecture to discover and develop novel, precision
therapeutics against both first-in-class and validated but intractable targets in genetically defined patient populations. We strive for speed and
efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences' value chain and shared
services. Jubilant Therapeutics is headquartered in the U.S. and comprised of a team of passionate, pioneering scientists. www.jubilantTx.com
Status of Proprietary Programs
Programs
Indication
Pathway
Current status Stage/remarks
Current pipeline
MEGFR
mutations
NSCLC and other kinase
tumors
Lead
LSD1/HDAC6
hematological
optimization
Epigenetics Pre-clinical
Addresses unmet need of patients developing resistance to kinase inhibitors. Lead
optimization in FY20 and ready for partnering.
-Dual Inhibitor
malignancies
and solid tumors
PDL-1
Multiple cancers Immuno-
Lead
oncology
PAD4
Inflammation,
auto immune
disorder
Epigenetics Lead
PRMT5
Lymphoma,
GBM
Epigenetics Lead
selection
optimisation
optimisation
Novel dual first in class epigenetic inhibitors of LSD1/HDAC6 to address unmet needs
in liquid cancers like acute myeloid leukaemia (AML) and select solid tumors. Pre-IND
studies including CMC initiated to enable potential Phase I clinical trial in FY21.
Small molecule therapy with comparable efficacy to large molecules with potentially
better safety profiles in initial studies. Further optimization and characterization of
lead molecule expected to be completed in FY20.
Potential to address unmet needs in multiple auto-immune disorders like rheumatoid
arthritis, psoriasis and atopic dermatitis. Demonstrated efficacy in various auto
immune-disorders in animal models. Preclinical candidate selection and IND enabling
studies expected in FY21.
Lead selection and pharmacology studies underway for further development in FY21
Partnered programs
BRD4
Liquid and solid
tumours
Epigenetics Preclinical
Partnered with Checkpoint Therapeutics in 2016 at lead stage with milestones.
Toxicology studies done. Pending partner decision for further studies towards clinic.
JUBILANT
LIFESCIENCESView entire presentation